Boehringer signs manufacturing agreement with MorphoSys

Published: 16-Mar-2011
Manufacturing Finance Pharmaceutical

Covers process development and manufacturing of clinical material for MOR208 antibody


German pharmaceutical firm Boehringer Ingelheim has signed a biopharmaceutical manufacturing agreement for therapeutic antibodies with biotechnology firm MorphoSys, based in Munich.

The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's MOR208, a monoclonal anti-CD19 antibody for the treatment of chronic lymphocytic leukaemia and potentially other B-cell malignancies. MorphoSys's partner Xencor is currently evaluating MOR208 in a phase 1 clinical trial in the US.

Simon Sturge, corporate senior vice president of the biopharmaceuticals division at Boehringer Ingelheim, said the combination of MorphoSys's successful track record in the discovery and clinical development of antibody-based therapeutics and the company’s proven competence in technical development and manufacturing will be an optimal fit.

  • Companies:
  • MorphoSys AG
  • Boehringer Ingelheim
See more

You may also like

Manufacturing

Oxford BioTherapeutics and Boehringer Ingelheim extend cancer immunology partnership

Read more
The two companies have extended their existing collaboration by a further two years, aiming to develop novel cancer immunotherapies

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Manufacturing

Oxford BioTherapeutics and Boehringer Ingelheim extend cancer immunology partnership

The two companies have extended their existing collaboration by a further two years, aiming to develop novel cancer immunotherapies
Manufacturing

ProBioGen enters technology collaboration with Boehringer Ingelheim

It contributes to Boehringer Ingelheim's goal of using cutting-edge technologies across the whole biopharmaceutical value chain
Research & Development

BioMed X and Boehringer Ingelheim initiate brain sensor project

Two projects are already underway between the research partners, including one in immunology and one in neuroscience
Research & Development

Boehringer Ingelheim and OBT advance oncology candidate

The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by Oxford BioTherapeutics’ proprietary OGAP target discovery platform
Manufacturing

Bilfinger supports construction of Boehringer vaccine plant

The equipment, tailored to Boehringer’s specific customer requirements, includes 34 virus culture and downstream processing tanks as well as ready-to-use modules called skids
Finance

Nanoform to initiate PoC studies for Boehringer Ingelheim projects

The two companies have executed a master services agreement to initiate projects in the pre-clinical early development space
Research & Development

Boehringer Ingelheim and Google partner for Pharma R&D

The partnership will focus on the companies’ complementary quantum computing capabilities
Subscribe now